FENNEC PHARMACEUTICALS INC. (FENC) Financial Statements
FENNEC PHARMACEUTICALS INC. (FENC) reported trailing twelve-month revenue of $59.2M (up 77.8% year on year) and net income of -$3.3M as of 2026-06-30, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
FENCFENNEC PHARMACEUTICALS INC.Follow FENC — free
—
Price chart with a free account
- Market cap
- 353.5M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 5 Nov, in 12 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2020 Dec 20 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|
| Revenue | 0.2 | 1.5 | 21.3 | 47.5 | 44.6 | 59.2 | |
| Gross profit | — | 1.4 | 20.0 | — | — | — | |
| Research & development | 5.1 | 3.5 | 0.1 | 0.3 | 0.3 | 0.2 | |
| Operating income | -17.9 | -22.6 | -12.8 | 2.6 | -6.3 | -1.1 | |
| Pre-tax income | -18.1 | -23.7 | -16.0 | -0.1 | -9.6 | -3.1 | |
| Income tax | 0.0 | 0.0 | — | 0.4 | 0.1 | 0.1 | |
| Net income | -18.1 | -23.7 | -16.0 | -0.4 | -9.7 | -3.3 | |
| Diluted EPS ($) | -0.76 | -0.90 | -0.60 | -0.02 | -0.34 | -0.09 | |
| Diluted shares (mn) | 23.7 | 26.3 | 26.6 | 27.3 | 28.6 | — |
USD millions · SEC XBRL
FENNEC PHARMACEUTICALS INC. — questions
- What is FENNEC PHARMACEUTICALS INC.'s revenue?
- $59.2M over the twelve months to 2026-06-30, up 77.8% year on year, from its 10-Q and 10-K filings.
- What is FENNEC PHARMACEUTICALS INC.'s net income?
- -$3.3M over the twelve months to 2026-06-30.
- What are FENNEC PHARMACEUTICALS INC.'s diluted earnings per share?
- $-0.09 over the twelve months to 2026-06-30.
Every figure on this page comes from FENNEC PHARMACEUTICALS INC.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.